drugset / Trial / NCT01386333
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia
Phase 1
Completed
23 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Consortium of Canadian Centres for Clinical Cognitive Research · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Oxytocin is a hormone produced by the brain that appears to have important roles in social cognition and emotion in humans. In a pilot study, the effects of a single dose of oxytocin on measures of emotion recognition and behaviour in patients with Frontotemporal Dementia were investigated. The results from the pilot study suggested that oxytocin may be associated with a modest improvement in neuropsychiatric behaviours seen in patients with Frontotemporal Dementia. To further examine the safety and tolerability of oxytocin in this disorder, the present study will examine the safety and tolerability of three different doses of intranasal oxytocin administered to patients with Frontotemporal Dementia twice daily for 1 week.
Timeline
- Start
- 2011-06
- Primary completion
- 2013-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxytocin | Peptide | 24 iu | Intranasal |
| Subject | Oxytocin | Peptide | 48 iu | Intranasal |
| Subject | Oxytocin | Peptide | 72 iu | Intranasal |